How BEOVU May Help
help your vision
People experienced vision improvements with BEOVU
BEOVU was assessed in 2 clinical studies of 730 people with wet age-related macular degeneration (wet AMD). Both studies measured the mean change in best corrected visual acuity (ability to read letters on an eye chart) at Year 1.
Both studies also measured the percentage of people who maintained vision (defined as not losing 15 or more letters on an eye chart) at Year 1.
BEOVU offers a 3-month dosing schedule in the first year of treatment
The recommended dose for BEOVU is 6 mg received by monthly injection for the first 3 treatments. Thereafter, BEOVU is given once every 2-3 months.
All others who received BEOVU were on a 2-month dosing
Your doctor will determine the individual dosing schedule that's right for you
Find out how BEOVU works
Understanding wet AMD
What is vascular endothelial growth factor?
Vascular endothelial growth factor (VEGF) is a protein responsible for producing new blood vessels. An excess amount of VEGF results in abnormal blood vessel growth.
What is wet AMD?
In an eye with wet AMD, abnormal blood vessels grow and leak fluid in the back of the eye. This can cause damage to the macula and lead to the loss of central vision.
BEOVU blocks VEGF
BEOVU blocks a type of VEGF to help slow the growth of new blood vessels, which may help to prevent fluid leaking into the macula.